摘要
我国原发性肝癌导致的死亡率仅次于肺癌，居第二位，已成为威胁我国国民健康最主要的恶性肿瘤之一。早期诊断和治疗可显著改善原发性肝癌的预后。异常糖基化水平与恶性肿瘤的发生发展密切相关，随着蛋白质组学和糖组学检测技术的进步，越来越多的异常糖基化结构及丰度变化在肝癌患者血清中被发现，如岩藻糖、唾液酸及多天线糖链水平的升高等。异常糖基化产物及代谢通路分子，如糖链、糖基转移酶及糖基化特定蛋白等有望作为新型肝癌血清标志物实现临床转化应用，在原发性肝癌早期诊断、动态监测、预后评估中具有重要应用前景。
Primary liver cancer （PLC） is the second leading cause of cancer death in China, and is one of the most serious threats to people＇s health. Early diagnosis and treatment can significantly improve the prognosis of PLC. Abnormal glycosylation is reported to be closely related to the genesis and development of malignant tumors. With the advent of modem proteomic and glycomic methodologies, several alterations in fucosylation, sialylation, and glycan branching have been observed in serum of patients with PLC. Altered glycosylation profiles, glycosyltransferases and glycosylated proteins could be screened and used as potential serum markers for early diagnosis, progression monitoring and prognosis evaluation of PLC.
出处
《中华检验医学杂志》
CAS
CSCD
北大核心
2016年第2期73-75,共3页
Chinese Journal of Laboratory Medicine
基金
国家自然科学基金，上海市科委项目(15JC1404100)National Natural Science Foundation of China，Shanghai Committee of Science and Technology
关键词
肝肿瘤
糖基化
糖基转移酶类
肿瘤标记
生物学
早期诊断
Liver Neoplasms
Glycosylation
Glycosyltransferases
Tumor Markers, Biological
Early Diagnosis
